NM_000551.4:c.355T>C
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PM1PM2PM5PP3_StrongPP5_Very_Strong
The NM_000551.4(VHL):c.355T>C(p.Phe119Leu) variant causes a missense change. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. F119S) has been classified as Likely pathogenic.
Frequency
Consequence
NM_000551.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 18 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
VHL | NM_000551.4 | c.355T>C | p.Phe119Leu | missense_variant | Exon 2 of 3 | ENST00000256474.3 | NP_000542.1 | |
VHL | NM_001354723.2 | c.*18-3259T>C | intron_variant | Intron 2 of 2 | NP_001341652.1 | |||
VHL | NM_198156.3 | c.341-3259T>C | intron_variant | Intron 1 of 1 | NP_937799.1 | |||
VHL | NR_176335.1 | n.684T>C | non_coding_transcript_exon_variant | Exon 3 of 4 |
Ensembl
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome Cov.: 31
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Von Hippel-Lindau syndrome Pathogenic:1
Variant summary: The c.355T>C (F119L) in VHL is a missense variant involving a highly conserved nucleotide and 3/4 in silico tools predict this variant to be deleterious (no prediction for SIFT). The variant was not found in the general population but was reported in at least 3 VHL patients. Another variant, c.357C>G, leading to the same amino acid change (F119L) and c.356T>C (F119S) have been reported in multiple VHL pts, indicating that this codon is a mutation hotspot. Additionally this variant has been identified as a somatic mutation in multiple renal cell carcinomas. Taken together, this is a disease variant and was classified as Pathogenic. -
Von Hippel-Lindau syndrome;C1837915:Chuvash polycythemia Pathogenic:1
This variant is also known as P190L. ClinVar contains an entry for this variant (Variation ID: 496059). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt VHL protein function. Experimental studies have shown that this missense change affects VHL function (PMID: 21715564, 23840444). For these reasons, this variant has been classified as Pathogenic. This missense change has been observed in individuals with VHL-related conditions (PMID: 7728151, 12000816, 16142346, 19270817). This sequence change replaces phenylalanine, which is neutral and non-polar, with leucine, which is neutral and non-polar, at codon 119 of the VHL protein (p.Phe119Leu). This variant is not present in population databases (gnomAD no frequency). -
Hereditary cancer-predisposing syndrome Pathogenic:1
The p.F119L pathogenic mutation (also known as c.355T>C), located in coding exon 2 of the VHL gene, results from a T to C substitution at nucleotide position 355. The phenylalanine at codon 119 is replaced by leucine, an amino acid with highly similar properties. In one study, in silico, in vitro, and bacterial assays showed that the p.F119L alteration results in loss of folding, stability, and function of the VHL protein (Shmueli MD et al. PLoS ONE. 2013 Jun;8:e66333). This mutation has been identified in multiple individuals/families with a clinical diagnosis or suspicion of von-Hippel-Lindau (VHL) syndrome (Cho HJ et al. J. Korean Med. Sci., 2009 Feb;24:77-83; Klein B et al. Hum. Genet., 2001 May;108:376-84; Ambry internal data). It has also been reported in a patient with non-syndromic pheochromocytoma (Neumann HP et al. N. Engl. J. Med. 2002 May; 346:1459-66), a patient with bilateral pheochromocytomas (Albattal S et al. Oncotarget, 2019 Oct;10:5919-5931), and a patient with bilateral adrenal pheochromocytoma and a carotid paraganglioma (Boedeker CC et al. J. Clin. Endocrinol. Metab. 2009 Jun; 94:1938-44). In one functional study, this alteration's interactions with hypoxia-inducible factors (HIF), which affect protein stability, were similar to at least one alteration classified as VLP at Ambry (W88C) (Rechsteiner MP et al. Cancer Res. 2011 Aug; 71(16):5500-11; Ambry internal data). Of note, this alteration is also designated as 568C>G in published literature. This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at